Severe rebound hypercalcemia following denosumab treatment in a paediatric patient with cervical aneurysmal bone cyst: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242298Keywords:
Hypercalcemia, Rebound hypercalcemia, Denosumab, Bisphosphonates, Aneurysmal bone cystsAbstract
Aneurysmal bone cysts (ABCs) are aggressive bone tumours often treated with denosumab, notably when surgical options are minimal. This case report describes an 8-year-old boy who developed severe hypercalcemia following denosumab treatment for a cervical ABC. Initially managed with surgery and chemotherapy, the patient experienced a significant rebound in calcium levels three months after denosumab cessation, leading to symptoms requiring intensive care. Management included intravenous fluids, calcitonin, and zoledronate, resulting in normalization of calcium levels and symptom resolution. This case highlights the need for vigilant monitoring of electrolyte levels and consideration of alternative therapies to prevent rebound hypercalcemia in paediatric patients.
References
Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: Mechanism of action and clinical outcomes. Int J Clin Prac. 2012;66(9):876-88.
Deodati A, Fintini D, Levtchenko E. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of denosumab. J Endocrinol Inves. 2002;45(2):159-66.
Yavropoulou MP, Yovos JG. The role of the WNT signaling pathway in osteoblast commitment and differentiation. Hormones. 2007;6(4):279-93.
Solberg LB, Stang E, Brorson SH, Andersson G, Reinholt FP. Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts and osteocytes. Histochemistry and Cell Biology. 2015;143(2):195-207.
Bakarman KA. Diagnosis and current treatment of aneurysmal bone cysts. Cureus. 2024;16(2):53587.
McClung MR. Cancel the denosumab holiday. Osteoporosis International. 2016;27(5):1677-82.
Boyce AM. Denosumab: an emerging therapy in pediatric bone disorders. Current Osteoporosis Reports. 2017;15(4):283-92.
Gandolfi A, Shaaban S. Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient. JCEM Case Reports. 2023;1(5):133.
Lerman MA, Francavilla M, Waqar-Cowles L, Levine MA. Denosumab treatment does not halt progression of bone lesions in multicentric carpotarsal osteolysis syndrome. JBMR Plus. 2023;7(5):10729.
Mariz BA, Migliorati CA, Alves FA, Penteado FM, Carvalho NPF, Santos-Silva AR, et al. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. Special Care in Dentistry. 2021;41(4):519-25.
Kurucu N, Akyuz C, Ergen FB, Yalcin B, Kosemehmetoglu K, Ayvaz M, et al. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases. Pediatric Blood and Cancer. 2010;65(4):26926.
Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Meta. 2018;103(2):596-603.
Wang R, Renouf DA. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer. Osteoporosis International. 2022;33(7):1625-9.
Harcus M, Aldridge S, Abudu A, Jeys L, Senniappan S, Morgan H, et al. The efficacy of denosumab in the management of a tibial paediatric aneurysmal bone cyst compromised by rebound hypercalcaemia. Case Reports in Pediatrics, 2020:1-6.
Seale E, Molina MO, Carsen S. Mitigating the denosumab-induced rebound phenomenon with alternating short and long-acting anti-resorptive therapy in a young boy with severe OI Type VI. Calcified Tissue International. 2023;112(6):613-20.
